

ResistancePlus[®] GC

N. gonorrhoeae + ciprofloxacin susceptibility

Smarter Diagnostics. Simplified Patient Care.

Up to 70% of gonorrhoea infections could be treated with ciprofloxacin, a simple oral antibiotic.¹⁻⁴



- Guidelines for gonorrhoea management call to preserve ceftriaxone and recommend use of ciprofloxacin when susceptibility information is available.^{5,6}
- Azithromycin resistance is rising, compromising dual-therapy options.^{5,7,8}
- Ciprofloxacin has higher efficacy for pharyngeal infections, a site where ceftriaxone is less effective.^{9,10}

ResistancePlus® GC is a multiplex qPCR test for detection of *Neisseria gonorrhoeae* and *gyrA* markers linked to ciprofloxacin susceptibility.¹¹⁻¹³ Dual *N. gonorrhoeae* targets improve clinical specificity, while ciprofloxacin resistance and susceptibility targets are included for additional confidence. **ResistancePlus® GC** is validated for a range of specimen types¹⁴ and powered by proprietary **PlexPCR®** technologies demonstrating improved multiplex performance compared with other probe-based tests.¹⁵

Single-well **PlexPCR®** test

Channel	Target
1	<i>N. gonorrhoeae</i> (Opa)
2	<i>N. gonorrhoeae</i> (PorA)
3	<i>gyrA</i> S91 wild type
4	<i>gyrA</i> S91F mutation
5	Internal Control

SpeedX Analysis for **ResistancePlus® GC**

Improve laboratory productivity with a validated software solution for automated result calling and simple data processing. Streamlined workflow to support rapid, routine diagnostics — with audit trails and user traceability. Included in kit costs and installed on a high security and GDPR compliant platform, with LIS compatibility.

Demonstrated clinical performance¹⁴

	GC Detection	<i>gyrA</i> Detection
Sensitivity	96.9%	100%
Specificity	99.7%	98.6%

Validated for urine, swabs (anal, rectal, cervical, vaginal, urethral, pharyngeal, eye) and extracts.¹⁴

- § A single test solution to determine infection and inform possible alternative treatment.
- § Options for patient testing algorithm include confirmatory or upfront partner testing.
- § Easily obtain resistance/susceptibility data on difficult to culture specimens.
- § Pack sizes to suit your test requirements with no minimum test volumes.
- § Positive, negative, and amplification control materials available.

ResistancePlus® GC Confirm infection and inform treatment

Product	Compatible	Size	Cat#
ResistancePlus® GC*	LC480 II	100 reactions	2011001
		25 reactions	2011025
	ABI 7500/ 7500 Fast/Dx	100 reactions	2013001
		25 reactions	2013025
ResistancePlus® GC Control	All platforms	10 reactions	95003
PlexPCR® Amplification Control	All platforms	400 reactions	90002

1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018. **2.** Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015 **3.** Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5 **4.** Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7):1-19 **5.** Fifer H. et al. 2018 UK national guideline for the management of infection with *Neisseria gonorrhoeae* (Draft). **6.** Bignell C. & Unemo M. 2012 European Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. **7.** Wi T. et al. PLoS Med 2017;14(7). **8.** Bolt H, et al. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567602/GRASP_Report_2016.pdf **9.** Lewis DA. Sex Transm Infect 2015;91:234-237. **10.** Whittles LK. Lancet Infect Dis. 2018 Jul;18(7):716-717. **11.** Allan-Blitz LT. Sex Transm Dis. 2017 May;44(5):261-265. **12.** Trembizki E et al. Lancet Infect Dis. 2016 Sep;16(9):1005-1006. **13.** Allan-Blitz LT et al. Clin Infect Dis. 2017 May 1;64(9):1268-1270. **14.** **ResistancePlus® GC** Instructions for use **15.** Tan LY. PLoS One. 2017 Jan 23;12(1):e0170087. *Not for sale in USA. **ResistancePlus® GC** kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR®** & **ResistancePlus®** are trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Australia - SpeedX Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Suite G16, National Innovations Centre
4 Cornwallis Street, Eveleigh,
Sydney, NSW 2015 Australia

Europe - SpeedX Ltd.

+44 (0)333 577 5210

sales.uk@speedx.com.au

Kemp House
152 - 160 City Road
London, EC1V 2NX, United Kingdom